[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@FutureMarketsRT Future Markets Research

Future Markets Research posts on X about spy, tariffs, trumps, $spy the most. They currently have XXX followers and XXX posts still getting attention that total XX engagements in the last XX hours.

Engagements: XX #

X Week XXX -XXXX%
X Month XXX +40%
X Months XXXXX -XX%
X Year XXXXX -XX%

Mentions: X #

Followers: XXX #

X Week XXX +0.75%
X Month XXX +4.70%
X Months XXX +22%
X Year XXX +40%

CreatorRank: undefined #

Social Influence #

Social category influence stocks finance countries

Social topic influence spy, tariffs, trumps, $spy, india, dr reddys, $rdy, sanofi, weight loss, $ptnt

Top assets mentioned SPDR S&P XXX ETF Trust (SPY) Dr. Reddy's Laboratories Limited American Depositary Shares (RDY) Sanofi (SNY)

Top Social Posts #

Top posts by engagements in the last XX hours

"#DRREDDY $RDY Dr. Reddy's Laboratories launched Sanofi's Beyfortus in India a preventive treatment for RSV in infants addressing a critical health need. This launch part of their partnership with Sanofi aligns with their strategy of expanding innovation and strengthens Dr. Reddys dual-track growth strategy in India. -- Paid Ad via #WallStWire: This account is operated by Wall Street Wire. Dr Reddys Laboratories or a related party has paid Wall Street Wire for ongoing promotional services. Full disclosures: Our content is not financial advice"
@FutureMarketsRT on X 2025-07-17 21:54:57 UTC XXX followers, XX engagements

"Potential tweet: Trump's EU tariff threats seem like a high-stakes chess game that could reshape global trade. European producers are caught in the crossfire with some markets potentially seeing 30-50% price increases. Challenging times ahead for international commerce. $SPY"
@FutureMarketsRT on X 2025-07-20 18:00:15 UTC XXX followers, XX engagements

"$PTNT Palatin Technologies announces positive preclinical data for oral MC4R agonist PL7737 in an animal model of obesity. PL7737 monotherapy produced rapid weight loss with additive effects when combined with tirzepatide. An IND submission is planned for Q4 2025 with clinical data expected in H1 2026. -- Paid Ad via #WallStWire: This account is operated by Wall Street Wire. Palatin Technologies or a related party has paid Wall Street Wire for ongoing promotional services. Full disclosures: Our content is not financial advice"
@FutureMarketsRT on X 2025-07-15 11:59:30 UTC XXX followers, XX engagements